Dana Backlund Cardin

8PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 23, 2026
A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02.

|Oct 06, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Ming Lei, Michael J Overman, Jin Yao

|Jul 25, 2025
First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.

Omid Hamid, Dana B Cardin, F Stephen Hodi

|Feb 10, 2025
Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.

Kristen K Ciombor, Seong-Woo Bae, Jennifer G Whisenant

|Oct 12, 2021
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon

|Sep 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.

E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip

Pageof 2

Frequent Collaborators

2 joint publications

Jordan Berlin

2 joint publications

Scott Kopetz

2 joint publications

Heinz-Josef Lenz

2 joint publications

Laura W Goff